Invion Ltd (IVX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.163x

Based on the latest financial reports, Invion Ltd (IVX) has a cash flow conversion efficiency ratio of -0.163x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.34 Million ≈ $-951.19K USD) by net assets (AU$8.25 Million ≈ $5.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Invion Ltd net asset quality index to measure how much of total assets are equity-financed.

Invion Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Invion Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IVX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Invion Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Invion Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Vast Renewables Limited Ordinary Shares
NASDAQ:VSTE
0.148x
Nanocap Group AB Series B
ST:NANOC-B
N/A
Quhuo Ltd
NASDAQ:QH
-0.059x
Begbies Traynor Group PLC
LSE:BEG
-0.014x
Himalaya Energi Perkasa Tbk PT
JK:HADE
-0.012x
Golden Goliath Resources Ltd.
V:GNG
-0.262x
Magnetite Mines Ltd
AU:MGT
-0.030x
Silver Castle Holdings Ltd
TA:SLCL
0.557x

Annual Cash Flow Conversion Efficiency for Invion Ltd (2006–2025)

The table below shows the annual cash flow conversion efficiency of Invion Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Invion Ltd (IVX) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$8.25 Million
≈ $5.84 Million
AU$-2.97 Million
≈ $-2.10 Million
-0.360x -116.34%
2024-06-30 AU$14.44 Million
≈ $10.22 Million
AU$-2.40 Million
≈ $-1.70 Million
-0.166x -68.80%
2023-06-30 AU$18.40 Million
≈ $13.02 Million
AU$-1.81 Million
≈ $-1.28 Million
-0.099x -73.98%
2022-06-30 AU$19.58 Million
≈ $13.85 Million
AU$-1.11 Million
≈ $-784.62K
-0.057x -164.92%
2021-06-30 AU$4.79 Million
≈ $3.39 Million
AU$417.98K
≈ $295.74K
0.087x +410.95%
2020-06-30 AU$5.43 Million
≈ $3.84 Million
AU$-152.47K
≈ $-107.88K
-0.028x +92.73%
2019-06-30 AU$5.46 Million
≈ $3.86 Million
AU$-2.11 Million
≈ $-1.49 Million
-0.386x -531.44%
2018-06-30 AU$7.91 Million
≈ $5.59 Million
AU$707.09K
≈ $500.31K
0.089x +245.01%
2017-06-30 AU$4.01 Million
≈ $2.84 Million
AU$-247.14K
≈ $-174.87K
-0.062x +90.36%
2016-06-30 AU$5.99 Million
≈ $4.24 Million
AU$-3.83 Million
≈ $-2.71 Million
-0.640x +56.67%
2015-06-30 AU$6.86 Million
≈ $4.85 Million
AU$-10.13 Million
≈ $-7.17 Million
-1.477x -244.59%
2014-06-30 AU$10.16 Million
≈ $7.19 Million
AU$-4.35 Million
≈ $-3.08 Million
-0.429x -36.75%
2013-06-30 AU$11.04 Million
≈ $7.81 Million
AU$-3.46 Million
≈ $-2.45 Million
-0.313x +82.26%
2012-06-30 AU$6.01 Million
≈ $4.25 Million
AU$-10.62 Million
≈ $-7.51 Million
-1.766x -128.12%
2011-06-30 AU$-2.14 Million
≈ $-1.52 Million
AU$-13.46 Million
≈ $-9.52 Million
6.281x +97.36%
2010-06-30 AU$-4.78 Million
≈ $-3.38 Million
AU$-15.20 Million
≈ $-10.76 Million
3.182x +4.10%
2008-06-30 AU$-3.23 Million
≈ $-2.28 Million
AU$-9.86 Million
≈ $-6.98 Million
3.057x +117.84%
2007-06-30 AU$715.28K
≈ $506.11K
AU$-12.26 Million
≈ $-8.67 Million
-17.134x -597.95%
2006-06-30 AU$4.83 Million
≈ $3.42 Million
AU$-11.87 Million
≈ $-8.40 Million
-2.455x --

About Invion Ltd

AU:IVX Australia Drug Manufacturers - Specialty & Generic
Market Cap
$2.36 Million
AU$3.34 Million AUD
Market Cap Rank
#29790 Global
#1727 in Australia
Share Price
AU$0.04
Change (1 day)
+0.00%
52-Week Range
AU$0.03 - AU$0.15
All Time High
AU$4.80
About

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more